Juniper Investment Company, LLC (Bartholdson John A., MICHAS ALEXIS P) purchased $5.1M of OFIX (indirect holdings)

Juniper Investment Company, LLC purchased 689,803 indirectly-held shares of Orthofix Medical Inc. (OFIX) at an average of $7.40 ($7.04–$7.41, $5.11M total) across 2 trades over 2026-11-09 to 2026-11-11. Filed jointly with Bartholdson John A. (10% owner) and MICHAS ALEXIS P (10% owner).

Original reporting
SEC EDGAR · Juniper Investment Company, LLC, Bartholdson John A., MICHAS ALEXIS P
Published Nov 12, 2026, 10:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 10:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OFIX
Bullish
medium confidence
Mentioned
$OFIX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OFIXBullishLow
01

Why it matters

The disclosed purchase adds to the cumulative insider ownership, which may be viewed positively by the market.

02

Market read

A material insider buy in a micro‑cap can influence short‑term price dynamics, though broader market impact is limited.

03

What to watch

Potential upcoming clinical data or regulatory events not disclosed in the filing.

Relevance 7/10Novelty 5/10Timing: after‑hours filing

Background

Form 4 filings provide the first public disclosure of insider transactions, offering insight into insider sentiment.

Company-level read

Ticker impact

$OFIXBullishMedium confidence
Context

Juniper Investment Company, LLC disclosed a $5.1M open‑market purchase of 689,803 shares, increasing its stake to 4,461,019 shares.

Expected impact

likely upward pressure as the market prices in the insider purchase

Evidence & confidence

A $5M purchase by a 10% owner is material for a micro‑cap and signals confidence, which can attract buyers.

Market effects

Minimal; reflects activity in the medical device sector but no broader impact.

None beyond the company's own share price.

Limited to investors tracking insider activity in small‑cap biotech.

Counterpoint

The purchase could be a strategic move unrelated to fundamentals, and the stock may still be overvalued.

Key entities

  • Juniper Investment Company, LLC

    Insider holder acquiring additional shares of OFIX.

  • Orthofix Medical Inc.

    Medical device manufacturer whose stock is affected by the insider purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Orthofix Medical Inc. Q3 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q3 2026 earnings below expectations due to U.S. Spine market softness and supplier delays. The company is consolidating distributors, with core partners generating 80% of U.S. spinal implant revenue. Updated full-year 2026 revenue guidance is $825M-$830M. Management expects a $22M net sales headwind in 2027 due to European MDR requirements. The VIRATA spinal implant system is set for full market launch in late Q4 2026.

$OFIXMedAI 8/10

Orthofix Medical (OFIX) Q3 2026 Earnings Call Transcript

Orthofix Medical (OFIX) reported Q3 2026 net sales of $207.9M, up 2.3% YoY. Spine sales fell 1%, while Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively. The company is focusing on strategic partnerships, simplifying its product portfolio, and aligning costs. It expects near-term sales pressure due to these transitions and updated guidance accordingly. Cash reserves stood at $86.9M.

$OFIXMed

Orthofix 3Q 2026: Revenue $207.86M, EPS ($0.15) — 10-Q Summary

Orthofix reported 3Q 2026 revenue of $207.86M, up 1.1% YoY, with a net loss of $6.07M, improved from $22.8M last year. Therapeutic Solutions and Global Limb Reconstruction sales grew, while Spinal Implants and other segments declined. Gross margin fell to 70.5% due to product mix changes. SG&A expenses decreased by $22.8M, driven by lower legal costs and commissions.

$OFIXMed

Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance

Orthofix Medical Inc. (OFIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance LEWISVILLE, Texas — November 9, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarte

$OFIXMed

Orthofix Medical Inc. Q2 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q2 2026 earnings call updates, emphasizing a shift toward distributor quality and asset utilization. Management expects 2026 net sales and EBITDA guidance to rise by $7 million, citing $12 million Medicare reimbursement restoration and $15 million European distributor benefit, partly offset by weaker smaller spine distributors. Medicare bone stimulator reimbursement was restored retroactive to May 18, 2026.